CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy

被引:5
|
作者
Yi, Yonglin [1 ]
Qiu, Zhengang [2 ]
Yao, Zifu [1 ,3 ]
Lin, Anqi [1 ]
Qin, Yimin [1 ]
Sha, Ruizhan [1 ]
Wei, Ting [1 ]
Wang, Yanru [1 ]
Cheng, Quan [4 ]
Zhang, Jian [1 ]
Luo, Peng [1 ]
Shen, Weitao [1 ]
机构
[1] Southern Med Univ, Zhujiang Hosp, Dept Oncol, Guangzhou, Peoples R China
[2] Gannan Med Univ, Affiliated Hosp 1, Dept Oncol, Guangzhou, Peoples R China
[3] Southern Med Univ, Clin Med Sch 1, Guangzhou, Peoples R China
[4] Ctr South Univ, Xiangya Hosp, Dept Neurosurg, Changsha, Peoples R China
基金
中国国家自然科学基金;
关键词
small cell lung cancer; CAMSAP1; platinum-based chemotherapy; drug sensitivity; biomarker; ACTIVATED PROTEIN-KINASE; TGF-BETA; B-CELLS; EXPRESSION; CHEMORESISTANCE; IMMUNOTHERAPY; SURVIVAL; FAMILY; MECHANISMS; MANAGEMENT;
D O I
10.3389/fcell.2021.770811
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Platinum-based chemotherapy is the first-line treatment for small cell lung cancer (SCLC). However, due to patients developing a resistance to the drug, most experience relapse and their cancer can become untreatable. A large number of recent studies have found that platinum drug sensitivity of various cancers is affected by specific gene mutations, and so with this study, we attempted to find an effective genetic biomarker in SCLC patients that indicates their sensitivity to platinum-based drugs. To do this, we first analyzed whole exome sequencing (WES) and clinical data from two cohorts to find gene mutations related to the prognosis and to the platinum drug sensitivity of SCLC patients. The cohorts used were the Zhujiang cohort (N = 138) and the cohort reported by George et al. (N = 101). We then carried out gene set variation analysis (GSVA) and gene set enrichment analysis (GSEA) to investigate possible molecular mechanisms through which these gene mutations affect patient prognosis and platinum drug sensitivity. We found that for SCLC patients, CAMSAP1 mutation can activate anti-tumor immunity, mediate tumor cell apoptosis, inhibit epithelial-mesenchymal transition (EMT), improve prognosis, and improve platinum drug sensitivity, suggesting that CAMSAP1 mutation may be a potential biomarker indicating platinum drug sensitivity and patient prognosis in SCLC.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapy
    Ishii, Hidenobu
    Azuma, Koichi
    Kawahara, Akihiko
    Matsuo, Norikazu
    Tokito, Takaaki
    Hoshino, Tomoaki
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (01) : 269 - 271
  • [2] Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapy
    Hidenobu Ishii
    Koichi Azuma
    Akihiko Kawahara
    Norikazu Matsuo
    Takaaki Tokito
    Tomoaki Hoshino
    Investigational New Drugs, 2021, 39 : 269 - 271
  • [3] Echocardiography and cardiac biomarkers in patients with non-small cell lung cancer treated with platinum-based chemotherapy
    Omersa, Daniel
    Cufer, Tanja
    Marcun, Robert
    Lainscak, Mitja
    RADIOLOGY AND ONCOLOGY, 2017, 51 (01) : 15 - 22
  • [4] Pretreatment serum syndecan-1 levels and outcome in small cell lung cancer patients treated with platinum-based chemotherapy
    Anttonen, A
    Leppä, S
    Ruotsalainen, T
    Alfthan, H
    Mattson, K
    Joensuu, H
    LUNG CANCER, 2003, 41 (02) : 171 - 177
  • [5] Haplotypes of BRCA1 and survival of non-small cell lung cancer patients treated with platinum-based chemotherapy
    Ryu, J.
    Shin, E.
    Lee, J.
    Yoo, Y.
    Cho, J.
    Kim, H.
    Lee, E.
    Kim, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] Association of polymorphisms in translesion synthesis genes with prognosis of advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy
    Zhang, Xuelin
    Chen, Qun
    Chen, Jia
    He, Chunya
    Mao, Jianlin
    Dai, Yuechu
    Yang, Xi
    Hu, Wei
    Zhu, Chengchu
    Chen, Baofu
    JOURNAL OF SURGICAL ONCOLOGY, 2016, 113 (01) : 17 - 23
  • [7] Thromboembolic events in lung cancer patients treated with platinum-based chemotherapy
    Rouis, Houda
    Kamoun, Hela
    Rejeb, Hadhemi
    Ben Tkhayat, Achraf
    Smadhi, Hanen
    Greb, Dorra
    Ben Abdelghaffar, Hajer
    Akrout, Ines
    Hassene, Hela
    Fekih, Leila
    Megdiche, Mohamed Lamine
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [8] XPG polymorphisms are associated with prognosis of advanced non-small cell lung cancer treated with platinum-based doublet chemotherapy
    Zou, H. Z.
    Zhao, Y. Q.
    GENETICS AND MOLECULAR RESEARCH, 2015, 14 (01) : 500 - 506
  • [9] Outcomes of second-line chemotherapy in Japanese patients with small cell lung cancer previously treated with platinum-based chemotherapy
    Haruyasu, Murakami
    Naito, Tateaki
    Kaira, Kyoichi
    Tsuya, Asuka
    Nakamura, Yukiko
    Takahashi, Toshiaki
    Endo, Masahiro
    Yamamoto, Nobuyuki
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S817 - S818
  • [10] Role of rs873601 Polymorphisms in Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy
    Zou, Ting
    Liu, Jun-Yan
    Qin, Qun
    Guo, Jie
    Zhou, Wen-Zhi
    Li, Xiang-Ping
    Zhou, Hong-Hao
    Chen, Juan
    Liu, Zhao-Qian
    BIOMEDICINES, 2023, 11 (12)